Furthermore, it had been observed that the treatment with anti-CCR5 antibody was able to inhibit the entry of CD14+CD16++ monocytes into plates in an experimental model of atherosclerosis (Weber et al., 2000; Tacke et al., 2007). The gene discussed is CCR5; the disease is atherosclerosis.